All In Biotech

Drug Trial Radar · NCT02094443

Alisporivir With RBV in Chronic Hepatitis C Genotype 2 and 3 Participants for Whom Interferon is Not an Option

A Multicenter, Open-label, Randomized, 2-arm, Phase II Trial of Pharmacodynamics, Pharmacokinetics and Safety of Two Dose Regimens of DEB025/Alisporivir in Combination With Ribavirin Therapy in Chronic Hepatitis C Genotype 2 and 3 Patients Who Have Previously Failed Interferon Therapy or Are Intolerant or Unable to Take Interferon.

Last checked: Nov 19, 2026Latest source record: Oct 13, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

52

Actual

Start

Mar 2014

Primary completion

Apr 2015

Study completion Apr 2015

Sponsor

Lead sponsor
Debiopharm International SAIndustry
Sponsor type
Industry
First posted
Mar 21, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary purpose of this study is to evaluate the pharmacodynamic (i.e. hepatitis C virus (HCV) viral load), pharmacokinetic and safety profiles between two treatment groups receiving different doses of DEB025 in combination with ribavirin (RBV) during the first 12 weeks treatment in chronic hepatitis C genotype (GT)-2 and GT-3 patients who had previously failed interferon therapy or were intolerant or unable to take interferon.

Conditions

  • Hepatitis C
  • Liver Disease

Interventions

  • AlisporivirDrug

    ALV 100 and 200 mg soft gel capsules administered orally

  • RibavirinDrug

    RBV 200 mg tablets (weight-based dose: \< 75 mg = 1000 mg/day; ≥ 75 kg = 1200 mg/day) administered orally in a divided daily dose

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Hepatitis C Virus Ribonucleic Acid Viral Load at Week 12Time frame: Baseline, Week 12
  2. Change From Baseline in Alanine Aminotransferase (ALT) at Week 12Time frame: Baseline, Week 12

Locations

16 sites in 2 countries. Site status is shown where the registry gives one.

  • Novartis Investigative Site

    Bakersfield, California

  • Novartis Investigative Site

    Lancaster, California

  • Novartis Investigative Site

    San Diego, California

  • Novartis Investigative Site

    San Diego, California

  • Novartis Investigative Site

    St Louis, Missouri

  • Novartis Investigative Site

    Arlington, Texas

  • Novartis Investigative Site

    Houston, Texas

  • Novartis Investigative Site

    San Antonio, Texas

  • Novartis Investigative Site

    Newport News, Virginia

  • Novartis Investigative Site

    Seattle, Washington

  • Novartis Investigative Site

    Seattle, Washington

  • Novartis Investigative Site

    Clichy, France

  • Novartis Investigative Site

    Créteil, France

  • Novartis Investigative Site

    Lyon, France

  • Novartis Investigative Site

    Nice, France

  • Novartis Investigative Site

    Paris, France

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.